392 related articles for article (PubMed ID: 33647456)
1. Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity.
Murad JP; Tilakawardane D; Park AK; Lopez LS; Young CA; Gibson J; Yamaguchi Y; Lee HJ; Kennewick KT; Gittins BJ; Chang WC; Tran CP; Martinez C; Wu AM; Reiter RE; Dorff TB; Forman SJ; Priceman SJ
Mol Ther; 2021 Jul; 29(7):2335-2349. PubMed ID: 33647456
[TBL] [Abstract][Full Text] [Related]
2. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
[TBL] [Abstract][Full Text] [Related]
3. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer.
Abate-Daga D; Lagisetty KH; Tran E; Zheng Z; Gattinoni L; Yu Z; Burns WR; Miermont AM; Teper Y; Rudloff U; Restifo NP; Feldman SA; Rosenberg SA; Morgan RA
Hum Gene Ther; 2014 Dec; 25(12):1003-12. PubMed ID: 24694017
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.
Hillerdal V; Ramachandran M; Leja J; Essand M
BMC Cancer; 2014 Jan; 14():30. PubMed ID: 24438073
[TBL] [Abstract][Full Text] [Related]
5. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
6. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft.
Zhou JE; Yu J; Wang Y; Wang H; Wang J; Wang Y; Yu L; Yan Z
Biomed Pharmacother; 2021 May; 137():111339. PubMed ID: 33550044
[TBL] [Abstract][Full Text] [Related]
7. Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer.
Shah Z; Tian L; Li Z; Jin L; Zhang J; Li Z; Barr T; Tang H; Feng M; Caligiuri MA; Yu J
Cell Stem Cell; 2024 Jun; 31(6):803-817.e6. PubMed ID: 38663406
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
[TBL] [Abstract][Full Text] [Related]
9. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
Wehrli M; Guinn S; Birocchi F; Kuo A; Sun Y; Larson RC; Almazan AJ; Scarfò I; Bouffard AA; Bailey SR; Anekal PV; Montero Llopis P; Nieman LT; Song Y; Xu KH; Berger TR; Kann MC; Leick MB; Silva H; Salas-Benito D; Kienka T; Grauwet K; Armstrong TD; Zhang R; Zhu Q; Fu J; Schmidts A; Korell F; Jan M; Choi BD; Liss AS; Boland GM; Ting DT; Burkhart RA; Jenkins RW; Zheng L; Jaffee EM; Zimmerman JW; Maus MV
Clin Cancer Res; 2024 May; 30(9):1859-1877. PubMed ID: 38393682
[TBL] [Abstract][Full Text] [Related]
10. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.
Weimin S; Abula A; Qianghong D; Wenguang W
Cancer Biol Ther; 2020 Jun; 21(6):570-580. PubMed ID: 32208880
[No Abstract] [Full Text] [Related]
11. [
Zettlitz KA; Tsai WK; Knowles SM; Salazar FB; Kobayashi N; Reiter RE; Wu AM
Mol Imaging Biol; 2020 Apr; 22(2):367-376. PubMed ID: 31209779
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.
Hillerdal V; Essand M
BioDrugs; 2015 Apr; 29(2):75-89. PubMed ID: 25859858
[TBL] [Abstract][Full Text] [Related]
13. RNA interference targeting PSCA suppresses primary tumor growth and metastasis formation of human prostate cancer xenografts in SCID mice.
Zhao Z; He J; Kang R; Zhao S; Liu L; Li F
Prostate; 2016 Feb; 76(2):184-98. PubMed ID: 26477693
[TBL] [Abstract][Full Text] [Related]
14. Engineered T cells for pancreatic cancer treatment.
Katari UL; Keirnan JM; Worth AC; Hodges SE; Leen AM; Fisher WE; Vera JF
HPB (Oxford); 2011 Sep; 13(9):643-50. PubMed ID: 21843265
[TBL] [Abstract][Full Text] [Related]
15. CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma.
Raj D; Nikolaidi M; Garces I; Lorizio D; Castro NM; Caiafa SG; Moore K; Brown NF; Kocher HM; Duan X; Nelson BH; Lemoine NR; Marshall JF
Clin Cancer Res; 2021 Mar; 27(5):1538-1552. PubMed ID: 33479048
[TBL] [Abstract][Full Text] [Related]
16. An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells.
Jureczek J; Bergmann R; Berndt N; Koristka S; Kegler A; Puentes-Cala E; Soto JA; Arndt C; Bachmann M; Feldmann A
Sci Rep; 2019 Jul; 9(1):10547. PubMed ID: 31332252
[TBL] [Abstract][Full Text] [Related]
17. Human prostate stem cell antigen and HSP70 fusion protein vaccine inhibits prostate stem cell antigen-expressing tumor growth in mice.
Dong L; Zhang X; Ren J; Wu S; Yu T; Hou L; Fu L; Yi S; Yu C
Cancer Biother Radiopharm; 2013 Jun; 28(5):391-7. PubMed ID: 23701419
[TBL] [Abstract][Full Text] [Related]
18. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
[TBL] [Abstract][Full Text] [Related]
19. Tandem CAR-T cells targeting MUC1 and PSCA combined with anti-PD-1 antibody exhibit potent preclinical activity against non-small cell lung cancer.
Wang A; Lv T; Song Y
Cell Immunol; 2023; 391-392():104760. PubMed ID: 37660477
[TBL] [Abstract][Full Text] [Related]
20. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma.
Raj D; Yang MH; Rodgers D; Hampton EN; Begum J; Mustafa A; Lorizio D; Garces I; Propper D; Kench JG; Kocher HM; Young TS; Aicher A; Heeschen C
Gut; 2019 Jun; 68(6):1052-1064. PubMed ID: 30121627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
